| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Pyxis Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Common Warrants to Purchase up to 49,310,352 Shares of Common Stock |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) |
| 08 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Exhibit B – Form of Common Warrant Exhibit C – Form of Registration Rights Agreement |
| 15 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 15, 2026, Pyxis Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 20, 2026, the Company’s rec... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a... |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 |
| 06 Feb 2026 |
8-K: Financial Statements and Exhibits
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity |
| 18 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of ... |
| 04 Aug 2025 |
8-K: Other Events
On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.’s (the “Company”) Phase 1 monotherapy clinical trial to evaluate micvotabart pelidotin (“MICVO”, formerly PYX-201) were made available on Clin... |
| 03 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 1, 2025, Pamela Connealy, the Chief Financial Officer and Chief Operating Officer of Pyxis Oncology, Inc. (the “Company”), |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, Pyxis Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders at 09:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 21, 2025, the Company’s rec... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death |
| 24 Mar 2025 |
8-K: Regulation FD Disclosure
Building a Differentiated ADC Company Nasdaq: PYXS March 2025 Exhibit 99.1 |
| 18 Mar 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and nec... |
Loading...